Curasight is a company engaged in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). Its technology provides diagnosis and risk stratification in multiple cancer types, especially in prostate cancer.